borsaitaliana.it From:
Cell T. has signed an agreement with pharmaceutical manufacturing NerPharMa for its drug candidate pixantrone.
The five-year contract signed, it said in a statement, covering the clinical and commercial supply of pixantrone. T. Cell pixantrone which is developing a treatment option for patients with aggressive non-Hodgkin's lymphoma relapsed or refractory, is preparing to submit an application later this year for marketing authorization in the EU and U.S. plans to begin a Phase III pixantrone in patients with relapsed or refractory aggressive lymphoma. Cell
T. had already 'announced on June 14 2010 that the Italian Drug Agency, the national body responsible for the regulation of drugs in Italy, has approved the facilities for the production of NerPharMa pixantrone. com / alb
Read Original borsaitaliana.it
0 comments:
Post a Comment